How to choose the version of Osimertinib/Taressa

Osimertinib/Tagrisso (Osimertinib) is an oral targeted drug used to treat non-small cell lung cancer (NSCLC). It is mainly used in patients with EGFR mutation-positive advanced or metastatic NSCLC. There are two versions of Osimertinib to choose from, namely the original drug and the generic drug. The common packaging specifications are 80mg 30 tablets and 40mg 30 tablets, etc. The two versions are basically the same in terms of ingredients and efficacy, but there may be some subtle differences. Choosing the appropriate version depends primarily on the patient's specific situation and the doctor's recommendations.

With oral medications, convenience of administration is a consideration. Osimertinib is a prescription drug, so it is only available by prescription. Patients should take 80 mg once a day for as long as the disease improves or remains stable, or there is no recurrence after surgery, and the side effects are tolerable. Some patients may prefer smaller dose tablets, while others may prefer to take fewer pills.

In addition, original drugs are usually produced and sold by original R&D companies, and their quality and efficacy are highly reliable. However, the price of the original drug is relatively high and may not be suitable for the financial affordability of all patients. The price range of each box of the original osimertinib drug currently on the domestic market and covered by medical insurance is approximately RMB 4,000 to 6,000 yuan. In comparison, generic drugs are produced by other pharmaceutical companies after the patent protection period of the original drug has expired, and the price is relatively low. The price of 80mg*30 tablets produced by Laos, Bangladesh and other pharmaceutical manufacturers is only about 800 yuan (the price may fluctuate due to the exchange rate). In terms of cost performance, the price of generic drugs is relatively high.